Results 71 to 80 of about 15,263 (254)

Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. [PDF]

, 2020
BACKGROUND & AIMS Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States.
Safroneeva, Ekaterina, Rothenberg, Marc E, Peterson, Kathryn, Zhao, Qiong, Stahl, Neil, Falk, Gary W, Assouline-Dayan, Yehudith, Dellon, Evan S, Graham, Neil M H, Hamilton, Jennifer D, Chen, Zhen, Hirano, Ikuo, Swanson, Brian N, Radin, Allen, Yancopoulos, George D, Pirozzi, Gianluca, Akinlade, Bolanle, Collins, Margaret H, Chehade, Mirna, Mannent, Leda, Schoepfer, Alain M   +20 more
core   +2 more sources

Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency

JEADV Clinical Practice, EarlyView.
ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz, Lars Matthies, Andrea Vanegas Ramirez   +2 more
wiley   +1 more source

Dupilumab Induced Psoriasiform Dermatitis [PDF]

, 2019
Atopic dermatitis (AD) is a common inflammatory skin condition that affects up to 20-30% of children and 2-10% of adults. In the past, therapeutic options were limited to emollients, topical glucocorticoids and calcineurin inhibitors, phototherapy, and ...
Veenstra, Jesse, Kerr, Holly, Novice, Karlee, Siegel, Dana   +3 more
core   +1 more source

A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab

Respiratory Medicine Case Reports
Dupilumab inhibits interleukin-4Rα and suppresses type 2 inflammation. Careful administration of dupilumab is required because it increases the blood eosinophil count secondary to a decrease in local eosinophil counts, sometimes resulting in eosinophilic
Daiki Nakashima, Eri Mori, Nobuyoshi Otori   +2 more
doaj   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Dupilumab: a novel treatment for asthma

, 2014
Alessandro Vatrella,1 Immacolata Fabozzi,1 Cecilia Calabrese,2 Rosario Maselli,3 Girolamo Pelaia3 1Department of Medicine and Surgery, University of Salerno, Salerno, 2Department of Cardiothoracic and Respiratory Sciences, Second University of Naples ...
Vatrella A, Maselli R, Calabrese C, Fabozzi I, Pelaia G   +4 more
core  

Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Lichen amyloidosis (LA) is a chronic, pruritic dermatosis with papillary dermal amyloid deposition. Standard therapies often fail, and most reports of dupilumab in LA involve patients with concomitant atopic dermatitis. We report a 32‐year‐old man with refractory, non‐atopic LA who had failed topical corticosteroids, tacrolimus, phototherapy ...
Sohrab Elahwiesy, Franziska Jochims, Manfred Kunz, Susann Forkel, Jan‐Christoph Simon, Benjamin Klein   +5 more
wiley   +1 more source

Outcomes of Upadacitinib following Dupilumab for Dupilumab-Associated Facial and Neck Erythema: A Systematic Review

Dupilumab, an anti-IL-13 and anti-IL-4 antibody, is a mainstay of treatment for moderate-to-severe atopic dermatitis. However, dupilumab-associated facial and/or neck erythema (DA-FNE) has been reported to be a relatively common adverse event. There have
Simpson, R (via Mendeley Data)
core   +5 more sources

Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study

Allergology International
Background: Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label extension
Yoko Kataoka, Motohiro Ebisawa, Akio Tanaka, Mizuho Nagao, Elizabeth Laws, Hisakatsu Nawata, Kazuhiko Arima, Daisuke Watanabe, Xin Lu, Jennifer Maloney, Ariane Dubost-Brama, Ashish Bansal, Kenji Yahata   +12 more
doaj   +1 more source

The Application of Dupilumab to Pediatric Patients Aged 6–11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far

Drug Design, Development and Therapy, 2023
Sarah Balboul,1 Julia Kahn,1 Alexis Tracy,2 Anjelica Peacock,3 Abigail Cline2– 4 1School of Medicine, New York Medical College, Valhalla, NY, USA; 2Department of Dermatology, New York Medical College, Valhalla, NY, USA; 3Department of Dermatology ...
Balboul S, Kahn J, Tracy A, Peacock A, Cline A   +4 more
doaj